Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Open Access
- 1 November 2010
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (11) , 1855-1858
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099Journal of Clinical Oncology, 2010
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancerJournal of Clinical Investigation, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of GefitinibJournal of Clinical Oncology, 2007
- Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Epidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer PatientsClinical Cancer Research, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor MutationsJNCI: Journal of the National Cancer Institute, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005